Dual-agonist occupancy of orexin receptor 1 and cholecystokinin A receptor heterodimers decreases G-protein-dependent signaling and migration in the human colon cancer cell line HT-29 by Bai, Bo et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/87270                               
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions. 
 
© 2019 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/. 
 
 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
1.1	Introduction
G-protein–coupled	receptors	 (GPCRs)	respond	to	a	variety	of	external	stimuli	and	endogenous	 ligands	and	activate	G-proteins.	 In	response	 to	 their	 ligands,	GPCRs	undergo	 ligand-dependent	conformation
changes	and	dimerization.	Dimerization	is	a	critical	aspect	of	GPCR	structure	and	function,	and	has	implications	for	receptor	trafficking	and	signaling.
GPCRs	form	heterodimers	as	well	as	homodimers.	For	example,	GPR103	and	OX1R	heterodimerize,	as	do	apelin	receptor	and	bradykinin	1	receptor	[1,2].	GPCR	heterodimers	can	exhibit	elevated	activity	or
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Abstract
The	orexin	(OX1R)	and	cholecystokinin	A	(CCK1R)	receptors	play	opposing	roles	in	the	migration	of	the	human	colon	cancer	cell	line	HT-29,	and	may	be	involved	in	the	pathogenesis	and	pathophysiology
of	cancer	cell	invasion	and	metastasis.	OX1R	and	CCK1R	belong	to	family	A	of	the	G-protein–coupled	receptors	(GPCRs),	but	the	detailed	mechanisms	underlying	their	functions	in	solid	tumor	development
remain	unclear.	In	this	study,	we	investigated	whether	these	two	receptors	heterodimerize,	and	the	results	revealed	novel	signal	transduction	mechanisms.	Bioluminescence	and	Förster	resonance	energy
transfer,	as	well	as	proximity	ligation	assays,	demonstrated	that	OX1R	and	CCK1R	heterodimerize	in	HEK293	and	HT-29	cells,	and	that	peptides	corresponding	to	transmembrane	domain	5	of	OX1R	impaired
heterodimer	formation.	Stimulation	of	OX1R	and	CCK1R	heterodimers	with	both	orexin-A	and	CCK	decreased	the	activation	of	Gαq,	Gαi2,	Gα12,	and	Gα13	and	the	migration	of	HT-29	cells	in	comparison	with
stimulation	with	orexin-A	or	CCK	alone,	but	did	not	alter	GPCR	interactions	with	β-arrestins.	These	results	suggest	that	OX1R	and	CCK1R	heterodimerization	plays	an	anti-migratory	role	in	human	colon
cancer	cells.
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novel	 function.	 For	 example,	 dopamine	 receptor	 D2R	 and	 somatostatin	 receptor	 SSTR5	 interact	 physically	 through	 hetero-oligomerization,	 resulting	 in	 elevated	 functional	 activity	 in	 response	 to	 dopamine	 and
somatostatin	[3].
Orexin-A	and	 -B,	neuropeptides	secreted	by	orexin	neurons,	bind	 to	 the	GPCRs	orexin	 receptor	1	 (OX1R)	and	2	 (OX2R).	OX1R	primarily	couples	with	Gαq,	whereas	OX2R	couples	with	Gαq,	Gαi,	 and	Gαs
subunits	[4].	Orexin	receptors	are	expressed	in	human	colon	cancer	cell	lines,	and	orexin	stimulation	plays	important	roles	in	regulating	various	behavioral	and	physiological	responses	of	colon	cancer	cells,	including
migration,	proliferation,	and	invasion	[5].
Cholecystokinin	 receptors	 are	 upregulated	 in	many	human	digestive	malignancies.	Clinicopathological	 analysis	 revealed	 that	 elevated	 expression	 of	 the	 cytoplasmic	 cholecystokinin	 receptors	CCK1R	and
CCK2R	correlated	significantly	with	indicators	of	colon	cancer	severity,	including	depth	of	tumor	invasion,	venous	invasion,	and	stage	of	progression	[6].	In	addition,	immunohistochemical	staining	showed	that	nuclear
CCK1R	 expression	 is	 significantly	 associated	with	 lymphatic	 invasion,	 stage	 of	 progression,	 and	 poorer	 survival.	 Together,	 these	 findings	 indicate	 that	 nuclear	 CCK1R	 represents	 a	 potential	 biomarker	 for	 poor
prognosis	in	patients	with	colon	cancer,	and	suggest	that	CCK1R	plays	an	important	role	in	colon	carcinogenesis.	Furthermore,	stimulation	of	CCK2R	promotes	human	colon	cancer	cell	growth	via	cyclooxygenase-2
induction	and	stimulation	of	prostaglandin	E2	production,	providing	further	evidence	that	cholecystokinin	receptors	possess	tumor-promoting	activities	in	colon	cancer	[7].
Collectively,	these	findings	suggest	that	the	functional	activities	of	OX1R	and	CCK1R	in	colon	cancer	cell	lines	are	due	to	dimerization.	To	test	this	hypothesis,	we	investigated	whether	these	two	receptors
heterodimerize,	and	our	 results	 revealed	novel	 signal	 transduction	mechanisms.	 In	addition,	we	examined	whether	a	novel	heterodimerization-mediated	signal	 transduction	 is	 involved	 in	 the	migration	of	human
cancer	cells.
2.2	Materials	and	methods
2.1.2.1	Reagents,	plasmids,	agonists,	and	antibodies
Human	orexin-A	and	CCK	(26–33)	were	purchased	 from	Phoenix	Pharmaceuticals	 (Belmont,	CA,	USA).	Plasmids	pcDNA3.1-OX1R	and	pcDNA3.1-CCK1R	were	obtained	 from	the	UMR	cDNA	Resource	Center	 (University	of
Missouri-Rolla,	USA).	Lipofectamine	2000	was	obtained	 from	 Invitrogen	 (Grand	 Island,	NY,	USA),	 and	Duolink	 II	 in	 situ	proximity	 ligation	assay	 (PLA)	detection	kits	were	obtained	 from	Sigma-Aldrich	 (St.	Louis,	MO,	USA).	Goat
polyclonal	anti-CCKAR	antibody	(NB100-2805)	was	obtained	from	Novus	Biologicals	(Littleton,	CO,	USA),	Goat	polyclonal	anti-α1B-AR	antibody	(sc-27136)	was	obtained	from	Santa	Cruz	Biotechnology	(Dallas,	TX,	USA),	anti-OX1R
antibody	(ab68718)	was	obtained	from	Abcam	(Cambridge,	UK),	and	anti-HA	and	anti-Myc	antibodies	were	obtained	from	Cell	Signaling	Technology	(Danvers,	MA,	USA).
OX1R-eGFP,	OX1R-Rluc,	CCK1R-Rluc,	CCK1R-eGFP,	α1B-AR-Rluc,	and	α1B-AR-eGFP	were	constructed	as	described;	all	 of	 these	constructs	encode	a	C-terminal	Renilla	 luciferase	or	eGFP	 tag	 [8].	Similarly,	 enhanced	cyan
fluorescent	protein	(eCFP)	was	attached	to	the	C-terminus	of	CCK1R	or	α1B-AR,	and	enhanced	yellow	fluorescent	protein	(eYFP)	to	the	C-terminus	of	OX1R,	by	inserting	the	ORF	of	CCK1R	or	α1B-AR	into	eCFP-N1	and	the	ORF	of
OX1R	into	eYFP-N1	(Clontech,	Mountain	View,	CA,	USA),	yielding	CCK1R-eCFP	or	α1B-AR-eCFP	and	OX1R-eYFP	[4],	respectively.
To	construct	hemagglutinin	(HA)-tagged	OX1R	and	Myc-tagged	CCK1R,	sequences	encoding	their	epitope	tags	(YPYDVPDYA	and	EQKLISEEDL,	respectively)	were	 inserted	 into	the	N-termini	of	pcDNA3.1-OX1R	and	pc3.1-
CCK1R,	respectively,	by	PCR.	The	sequences	of	the	resultant	constructs,	HA-OX1R	and	Myc-CCK1R,	respectively,	were	confirmed	by	commercial	sequencing.
To	construct	Gαi2-Rluc,	Gαq-Rluc,	Gαs-Rluc,	Gα12,	and	Gα13	fusion	proteins,	the	coding	sequence	of	humanized	Rluc8	(kindly	provided	by	Dr.	Sanjiv	Gambhir	of	the	Department	of	Nuclear	Medicine	of	Stanford	University)	was
PCR-amplified	and	inserted	into	the	coding	sequence	of	each	Gα	subunit.	Rluc	was	inserted	between	residues	91	and	92	of	Gαi2,	residues	97	and	98	of	Gαq,	residues	113	and	114	of	Gαs,	residues	115	and	116	of	Gα12,	and	residues
106	and	107	of	Gα13	[9].	All	constructs	were	confirmed	by	DNA	sequencing.
2.2.2.2	HIV	transactivator	of	transcription-linked	peptides
HIV	 TAT	 (YGRKKRRQRRR)	 was	 fused	 to	 the	 C-termini	 of	 the	 OX1R	 TM5	 and	 TM7	 peptides,	 yielding	 the	 amino	 acid	 sequences	 SCFFFVTYLAPLGLMGMAYFQIFYGRKKRRQRRR	 and
YACFTFSHWLVYANSAANPIIYNFYGRKKRRQRRR,	 respectively.	 The	 inserted	 peptides	were	 confirmed	 to	 have	 the	 correct	 orientation,	 because	HIV	 TAT	 binds	 to	 phosphatidylinositol-(4,5)-bisphosphate	 on	 the	 inner	 surface	 of	 the
membrane	[10].	After	custom	synthesis,	 the	 identity	of	each	TM	peptide	sequence	was	determined	using	a	LC-MS	system	(Shimadzu	2020	and	Waters	1010).	The	molecular	weights	of	TM	5	and	7	were	4209.11	and	4355.05	Da,
respectively.	As	shown	in	Fig.	3A	and	B,	all	TMs	were	synthesized	correctly.
2.3.2.3	Cell	culture	and	transfection
HEK293	and	HT-29	cells	were	cultured	in	Dulbecco’'s	modified	Eagle’'s	medium	(DMEM;	Gibco,	Invitrogen,	Paisley,	UK)	containing	10%	inactivated	fetal	bovine	serum	(FBS)	at	37	°C	with	5%	CO2.	The	cells	were	transiently
transfected	using	Lipofectamine	2000.	In	all	transfection	experiments,	the	total	amount	of	transfected	DNA	was	kept	constant	by	addition	of	the	appropriate	amount	of	empty	vector.
2.4.2.4	Enzyme-linked	immunosorbent	assay	(ELISA)
One	day	before	transfection,	HEK293	cells	were	plated	in	96-well	plates	at	a	density	of	1	×	104	cells	per	well.	Transient	transfection	to	express	HA-OX1R	and/or	Myc-CCK1R	was	performed	using	Lipofectamine	2000.	After	an
additional	24	h,	cells	were	fixed	for	30	min	at	room	temperature	with	4%	paraformaldehyde	 in	phosphate-buffered	saline	(PBS).	The	fixed	cells	were	washed	three	times	with	PBS,	and	nonspecific	binding	sites	were	blocked	with
blocking	buffer	 (3%	dry	milk	 in	PBS).	The	cells	were	 incubated	overnight	at	4	°C	with	 rabbit	polyclonal	 anti-HA	or	anti-Myc	primary	antibodies	 (1:500	each	 in	blocking	buffer),	washed	 three	 times	with	PBS,	 and	 incubated	with
peroxidase-conjugated	goat	or	rabbit	secondary	antibody	in	DMEM	(1:2000	in	blocking	buffer)	for	1	h	at	37	°C.	The	cells	were	then	incubated	with	200	μl	of	3,3’′,5,5’′-tetramethylbenzidine	(Sigma-Aldrich)	for	30	min	at	37	°C,	 the
enzymatic	reaction	was	stopped	by	adding	50	μl	of	2	N	H2SO4,	and	the	optical	density	of	each	well	at	450	nm	was	measured	using	an	iMark	Microplate	reader	(Bio-Rad,	Hercules,	California,	USA).	Optical	densities	were	kept	between
0.1	and	1.0	to	avoid	saturation.
2.5.2.5	Immunofluorescence	assay
HEK293	cells	were	transfected	with	OX1R-eGFP	and	Myc-CCK1R	plasmids	in	12-well	plates.	After	24	h,	the	cells	were	distributed	into	6-well	plates	at	a	density	of	5	×	105	cells/well	and	cultured	for	an	additional	24	h	on	glass
coverslips	 pre-treated	with	 0.1	mg/ml	 poly-D-lysine.	 The	 cells	 were	washed	 three	 times	 for	 5	min	 each	with	 PBS,	 fixed	with	 4%	 paraformaldehyde	 for	 10	min,	 and	 then	 blocked	with	 1%	 bovine	 serum	 albumin	 for	 1	 h	 at	 room
temperature.	The	coverslips	were	 incubated	with	rabbit	polyclonal	anti-Myc	primary	antibody	and	secondary	antibody	 labeled	with	Alexa	Fluor	594	(Red),	washed,	and	 incubated	with	4’′,6-diamidino-2-phenylindole	 (DAPI)	 to	 stain
nuclei.	After	additional	washing,	the	coverslips	were	mounted	onto	glass	microscope	slides	and	examined	using	a	Leica	DMRE	laser	scanning	confocal	microscope	(Leica,	Milton	Keynes,	UK).
2.6.2.6	In	situ	PLA
Endogenous	OX1R	and	CCK1R	expression	in	HT-29	cells	was	assayed	using	Duolink	II	in	situ	PLA	detection	kits.	Briefly,	HT-29	cells	were	fixed	in	4%	paraformaldehyde	for	15	min,	washed	with	PBS,	and	incubated	in	blocking
buffer	for	1	h	at	37	°C.	The	cells	were	subsequently	incubated	overnight	at	4	°C	with	goat	polyclonal	anti-CCK1R	antibody	(Novus	Biologicals)	and	rabbit	polyclonal	anti-OX1R	antibody	(Abcam).	After	washing	with	Duolink	II	buffer	A	at
room	temperature,	the	cells	were	incubated	at	37	°C	with	PLA	probes	detecting	rabbit	or	goat	antibodies	(Duolink	II	PLA	probe	anti-rabbit	plus	and	Duolink	II	PLA	probe	anti-goat	minus).	After	three	washes	with	buffer	A,	the	cells
were	incubated	for	1	h	at	37	°C	with	ligation	solution,	washed	with	buffer	A,	and	then	incubated	for	100	min	at	37	°C	with	amplification	solution.	The	cells	were	washed	twice	with	buffer	B,	immersed	in	0.01	×	Duolink	II	buffer	B,	and
mounted	using	Duolink	 II	Mounting	Medium	with	DAPI.	Punctate	 fluorescent	signals	 indicative	of	close	proximity	 (<	16	nm)	[11]	 between	OX1R	and	CCK1R	and	 suggesting	 the	 formation	 of	 heterodimers	were	 assessed	by	 laser
scanning	confocal	microscopy	(Leica	model	DMRE;	Leica,	Milton	Keynes,	UK).	Similar	methods	were	used	to	detect	the	presence	of	OX1R	and	CCK1R	heterodimers	 in	HEK293	cells	transfected	with	OX1R-	and	CCK1R-expressing
vectors.	HEK293	cells	expressing	OX1R	alone	or	OX1R	and	α1b-adrenoceptor	were	used	as	negative	controls.
To	explore	the	effects	of	TM	peptides	on	OX1R	and	CCK1R	dimerization,	HEK293	cells	were	transfected	with	the	plasmids	pcDNA3.1-OX1R	and	pcDNA3.1-CCK1R	in	12-well	plates.	After	24	h,	the	cells	were	distributed	into	6-
well	plates	and	treated	for	6	h	with	HIV	TAT–fused	TM	peptides	(10	μM)	corresponding	to	TM5	or	TM7	of	OX1R,	and	then	assayed	for	dimerization	as	described	above.
2.7.2.7	BRET	assays
HEK293	cells	were	transiently	transfected	with	Rluc-tagged	and	eGFP-	or	GFP2-tagged	constructs.	After	24	h,	the	cells	were	harvested	in	HEPES-buffered	Phenol	red–free	complete	medium	containing	5%	fetal	calf	serum
(FCS),	seeded	in	poly-D-lysine–coated	96-well	plates,	and	incubated	with	acceptor	pairs	(Table	S1).	Results	were	assessed	using	a	Mithras	LB940	plate	reader	(Berthold	Technologies,	Bad	Wildbad,	Germany)	and	the	MicroWin	2000
software,	as	described	[12,13].
Table	1	Substrates	and	filter	settings	used	in	BRET	assays.
alt-text:	Table	1
Method Donor Substrate Donor	Eemission	[nm] Acceptor Acceptor	Eemission	[nm]
BRET1 Rluc Coelenterazine	h 460 eGFP 535
BRET2 Rluc Deep	Blue	C™ 400 GFP2 515
eBRET Rluc EnduRen™ 460 eGFP 535
2.8.2.8	FRET	assays
FRET	assays	were	performed	as	described	[14–16].	Briefly,	the	donor	plasmid	CCK1R-eCFP	and	receptor	plasmid	OX1R-eYFP	were	co-transfected	into	HEK293	cells.	The	donor	and	acceptor	channels	were	used	to	eliminate
crosstalk	 in	 the	FRET	channel.	To	determine	calibration	coefficients	corrected	 for	excitation	and	emission	crosstalk,	CCK1R-eCFP	and	OX1R-eYFP	were	 transfected	 individually	 into	HEK293	cells	as	donor	and	acceptor	channels,
respectively.	After	12–24	h,	FRET	signals	were	detected	using	the	FRET	Kit	for	the	Leica	AM	TIRF	MC	system	(Leica	Microsystems).	The	efficiency	of	FRET	(EA(i))	was	calculated	using	the	following	equation:
where	A,	B,	and	C	correspond	to	the	intensities	of	the	three	signals	(donor,	FRET,	and	acceptor,	respectively),	and	α,	β,	γ,	and	δ	are	the	calibration	factors	generated	by	the	acceptor-	and	donor-only	references.
2.9.2.9	SRF-RE	and	NFAT-RE	luciferase	reporter	assays
In	luciferase	reporter	assays	for	serum	response	factor-response	element	(SRF-RE)	and	nuclear	factor	of	activated	T-cells-response	element	(NFAT-RE),	cells	expressing	OX1R,	CCK1R,	or	both	were	transfected	with	pSRF-RE-
Luc	or	pNFAT-Luc	PathDetect	plasmid	(Stratagene)	containing	the	indicated	response	elements	(REs)	upstream	of	firefly	luciferase,	along	with	pRL-Tk	(Promega),	which	encodes	Renilla	luciferase.	After	24	h,	the	cells	were	starved	and
stimulated	with	orexin-A	and/or	CCK	(26–33)	for	6	h	prior	to	harvesting.	Luciferase	activity	was	measured	as	described	[4].	Firefly	and	Renilla	luciferase	activities	were	measured	with	a	Dual-Luciferase	Reporter	(DLR)	Assay	System	on
a	FLUOstar	OPTIMA	microplate	reader	(Promega).
2.10.2.10	Real-time	analysis	using	the	xCELLigence	system
Prior	to	measurements,	the	xCELLigence	real-time	cell	analysis	(RTCA)	dual-purpose	(DP)	system	(ACEA)	was	initialized	according	to	the	manufacturer’'s	instructions.	HT-29	cells	were	plated	at	5	×	104	cells/well	in	100	μl	of
serum-free	medium	(upper	chamber)	and	allowed	to	migrate	toward	the	lower	chamber	(containing	5%	FBS)	for	24	h.	Cells	were	treated	with	agonists	as	indicated.	The	xCELLigence	system	monitors	the	electrical	impedance	of	the
gold-sensing	electrode	underneath	the	cultured	cell	 layer	and	calculates	the	arbitrary	cell	 index	(CI)	as	CI	=	(Zi		‐−	Z0)	/	15,	where	Zi	 represents	 the	electrical	 impedance	at	a	given	 time	point	and	Z0	represents	 the	background
electrical	impedance.
2.11.2.11	Statistical	analysis
All	data	are	shown	as	means	±	SEM.	Data	were	presented	and	analyzed	using	Prism	5.0	graphing	software	(GraphPad).	Sigmoidal	curves	were	fitted	to	the	dose-response	data	using	nonlinear	regression.	Statistical	analysis
was	performed	using	one-way	analysis	of	variance	followed	by	Tukey’'s	multiple	comparison	post-test.
3.3	Results
3.1.3.1	Co-expression	and	co-localization	of	OX1R	and	CCK1R	in	HEK293	cells
To	 rule	 out	 the	 possibility	 that	 co-expression	 of	 OX1R	 and	 CCK1R	 affects	 the	 expression	 levels	 and	membrane	 distribution	 of	 both	 receptors,	 we	 assessed	 cell	 surface	 expression	 of	 OX1R	 and	CCK1R	 by	 enzyme-linked
immunosorbent	assay	(ELISA)	using	anti-HA	and	-Myc	antibodies,	respectively.	Cell	surface	expression	was	unaffected	by	co-expression	of	both	proteins	in	HEK293	cells	(Fig.	1A).
Immunofluorescence	 image	 analysis	 of	HEK293	 cells	 co-expressing	C-terminal	 eGFP-tagged	OX1R	 and	N-terminal	Myc-tagged	CCK1R	 confirmed	 that	OX1R	 and	CCK1R	 co-localized	 on	 cell	membranes	 (Fig.	 1B).	 The	 cell
membrane	expression	of	both	proteins	suggested	that	the	two	receptors	might	interact.
3.2.3.2	Heterodimerization	of	OX1R	and	CCK1R	measured	by	BRET	assays
We	investigated	the	heterodimerization	of	OX1R	and	CCK1R	using	BRET	saturation	assays,	which	detect	protein–protein	interactions	in	living	cells.	We	also	observed	the	homodimerization	of	OX1R	and	CCK1R	in	the	same
manner.	HEK293	cells	were	co-transfected	with	a	constant	amount	of	 the	 luminescent	donor	(OX1R-Rluc)	and	 increasing	amounts	of	 the	fluorescent	acceptor	(CCK1R-eGFP,	OX1R-eGFP,	or	α1b-adrenoceptor-eGFP).	The	BRET	ratio
between	OX1R-Rluc	and	CCK1R-eGFP	increased	with	the	expression	of	CCK1R-eGFP	or	OX1R-eGFP	until	a	plateau	was	reached	(Fig.	2A).	Moreover,	the	BRET	ratio	of	homodimerization	of	OX1R	or	CCK1R	was	significantly	reduced.	In
the	negative	control	group,	however,	increasing	expression	of	α1b-adrenoceptor-eGFP	resulted	in	a	low	BRET	ratio,	suggesting	a	nonspecific	linear	relationship.	This	is	consistent	with	a	previous	report	that	BRET	signals	are	low	when
OX1R-Rluc8	and	α1b-adrenoceptor-eYFP	are	co-transfected	[17].	These	results	indicate	that	OX1R-Rluc	and	CCK1R-eGFP	can	form	heterodimers.	Receptor	constructs	in	the	“opposite”	configuration	(CCK1R-Rluc	and	OX1R-eGFP)	were
also	tested	to	confirm	the	dimerization	of	OX1R	and	CCK1R	(Fig.	2B).	As	reported	[18],	increasing	expression	of	secretin	receptor	(SecR-eGFP)	also	resulted	in	a	low	BRET	ratio.
Fig.	1	Co-expression	and	co-localization	of	OX1R	and	CCK1R	in	HEK293	cells.
(A)	ELISA	assays	of	cell	surface	expression	of	HA-OX1R	and	Myc-CCK1R.	Cells	were	transfected	with	HA-tagged	OX1R	and/or	Myc-tagged	CCK1R,	and	ELISA	assays	were	performed	on	intact	cells	using	anti-HA	and	anti-Myc	antibodies.	Data	represent
means	±	SEM	of	three	independent	experiments.	Statistical	analysis	was	performed	by	one-way	ANOVA	followed	by	Tukey’'s	multiple	comparison	post	hoc	test	(ns:	not	significant,	p	>	0.05).
(B)	Confocal	analysis	of	co-localization	of	OX1R	and	CCK1R	in	transfected	HEK293	cells.	C-terminally	eGFP-tagged	OX1R	and	N-terminally	Myc-tagged	CCK1R	were	expressed	in	HEK293	cells	and	visualized	using	laser	confocal	microscopy.	Confocal
images	of	OX1R	and	CCK1R	were	merged	to	show	regions	of	co-localization.	Nuclei	were	stained	with	the	DNA-specific	dye	DAPI	(blue).
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Additional	BRET	assays	were	performed	to	determine	whether	ligands	induce	heterodimerization.	BRET	ratios	were	observed	in	HEK293	cells	co-transfected	with	OX1R-Rluc	and	CCK1R-eGFP	at	a	1:3	ratio	and	treated	with
orexin-A,	in	cells	treated	with	CCK	(26–33)	alone,	and	in	cells	treated	for	10	min	with	orexin-A	and	CCK	(26–33)	(Fig.	2C).	The	BRET	ratios	of	these	cells	were	0.364	±	0.010,	0.361	±	0.009,	and	0.366	±	0.012,	respectively.	When	the
experiment	was	repeated	following	energy	donor–acceptor	exchange	between	the	two	receptors,	orexin-A	or/and	CCK	(26–33)-induced	BRET	ratios	remained	unchanged	(Fig.	2D).	These	results	implied	that	ligand	binding	might	not	be
Fig.	2	Heterodimerization	of	OX1R	and	CCK1R,	demonstrated	by	BRET	assays	in	live	cells.
(A	and	B)	HEK293	cells	were	co-transfected	with	a	constant	amount	of	the	OX1R-Rluc	(A)	or	CCK1R-Rluc	(B)	construct,	each	at	0.15	μg/well,	and	increasing	amounts	of	the	eGFP	construct	(0.15–0.9	μg/well).	Calculated	BRET	ratios	were	plotted	relative
to	total	fluorescence/luminescence	ratios,	and	data	were	analyzed	by	nonlinear	regression	curve	fitting	(one	site–specific	binding)	using	GraphPad	Prism.	BRET	ratios	were	analyzed	and	expressed	as	means	±	SEM	of	four	experiments.
(C	and	D)	Effects	of	orexin-A	and/or	CCK	(26–33)	on	BRET	ratios.	Plasmids	expressing	OX1R-Rluc	and	CCK1R-eGFP	(C)	or	CCK1R-Rluc	and	OX1R-eGFP	(D)	were	co-transfected	(1:3)	into	HEK293	cells.	Twenty-four	hours	later,	the	Rluc	substrate
coelenterazine-h	was	added	for	5	min,	and	the	cells	were	treated	with	orexin-A	(100	nM),	CCK	(26–33)	(1000	nM),	or	vehicle	for	10	min.	BRET	ratios	were	analyzed	and	expressed	as	means	±	SEM	of	four	experiments	(one-way	analysis	of	variance;	ns:	not
significant,	p	>	0.05).
(E	and	F)	Competition	binding	assay.	HEK293	cells	were	co-transfected	with	a	fixed	amount	of	CCK1R-Rluc	and	OX1R-eGFP	plasmids	and	increasing	amounts	of	OX1R	(C)	or	CCK1R	(D)	not	fused	to	a	donor	or	acceptor	BRET	probe.	Data	represent
means	±	SEM	of	three	independent	experiments.	**,	p	<	0.01	vs.	control	groups.
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necessary	for	heterodimerization	of	OX1R	and	CCK1R.	Moreover,	sequential	addition	of	orexin-A	and	CCK	(26–33)	did	not	similarly	alter	the	BRET	ratio	between	OX1R	and	CCK1R	(Fig.	S1).
To	perform	competitive	BRET	analysis,	we	co-expressed	 fixed	amounts	of	CCK1R-Rluc/OX1R-eGFP	and	 increasing	amounts	of	 unlabeled	OX1R	or	CCK1R	 in	HEK293	cells.	BRET	 signals	decreased	as	 the	 concentration	of
unlabeled	OX1R	or	CCK1R	increased	(Fig.	2E	and	F).	These	data	further	confirmed	the	specific	formation	of	OX1R	and	CCK1R	heterodimers.
Furthermore,	BRET	ratios	were	significantly	reduced	after	incubation	with	HIV	TAT–fused	TM5,	but	not	TM7	peptide,	for	each	energy	donor–acceptor	combination,	suggesting	that	TM5	impairs	the	heterodimerization	of	OX1R
and	CCK1R	(Fig.	3C	and	D).
3.3.3.3	Heterodimerization	of	OX1R	and	CCK1R	determined	by	FRET	assays
We	also	used	FRET	to	explore	the	interaction	between	OX1R	and	CCK1R.	For	these	FRET	assays,	HEK293	cells	were	transfected	with	OX1R-eYFP	and/or	CCK1R-eCFP.	Sites	of	interaction	on	the	acquired	FRET	images	are
marked	yellow	or	red,	with	more	intense	color	indicating	a	stronger	interaction	(Fig.	4A).	Lower	FRET	signals	were	observed	in	all	singly	transfected	cells	and	co-transfected	α1b-adrenoceptor-eCFP	and	OX1R-eYFP	cells,	whereas	FRET
signals	were	significantly	higher	in	cells	transfected	with	both	CCK1R-eCFP	and	OX1R-eYFP	(Fig.	4A	and	B),	further	confirming	that	OX1R	and	CCK1R	can	form	heterodimers.
Fig.	3	Effects	of	interfering	peptides	on	OX1R	and	CCK1R	heterodimers.
(A	and	B)	Identification	of	transmembrane	domain	(TM)	peptide	sequences.	Peptide	sequences	of	(A)	TM5	and	(B)	TM7	of	OX1R,	measured	by	liquid	chromatography–mass	spectrometry	(LC-MS).
(C	and	D)	HEK293	cells	were	co-transfected	with	OX1R-Rluc	and	CCK1R-eGFP	(C)	or	CCK1R-Rluc	and	OX1R-eGFP	(D)	and	incubated	at	37	°C	for	2	h	with	HIV	TAT–fused	TM	peptides	(10	μM)	corresponding	to	TM5	or	TM7	of	OX1R.	BRET	ratios	were
analyzed	and	expressed	as	means	±	SEM	of	four	experiments	(one-way	analysis	of	variance;	ns:	not	significant,	p	>	0.05;	**,	p	<	0.01	vs.	control	group).
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3.4.3.4	In	situ	PLA	confirms	formation	of	endogenous	OX1R	and	CCK1R	heterodimers	in	HT-29	cells
In	 situ	 PLA	 is	 sufficiently	 sensitive	 to	 detect	 molecular	 interactions	 between	 two	 endogenous	 proteins.	 In	 this	 regard,	 it	 is	 similar	 to	 immunoprecipitation,	 but	 it	 has	 the	 advantage	 that	 it	 does	 not	 require	 membrane
solubilization.	Labeling	heterodimers	by	PLA	requires	both	receptors	to	be	sufficiently	close	(<	16	nm)	to	allow	two	antibody–DNA	probes	to	form	double-stranded	segments.	The	signal	is	further	amplified	in	the	presence	of	fluorescent
nucleotides	[19].	First,	PLA	was	used	to	determine	the	expression	of	endogenous	OX1R	and	CCK1R	heterodimers	in	HT-29	cells.	OX1R–CCK1R	heterodimers	in	cultured	HT-29	cells	were	detected	as	red	punctate	staining	(Fig.	5A,	b).
As	expected,	red	dots	were	also	detected	in	HEK293	cells	stably	co-expressing	both	OX1R	and	CCK1R	(Fig.	5B,	c),	as	well	as	in	cells	expressing	only	OX1R	or	OX1R	and	α1b-adrenoceptor,	used	as	controls	(Fig.	5B,	a	and	b),	suggesting
that	endogenous	OX1R–CCK1R	heterodimers	were	present	in	both	cell	lines.	Pre-incubation	with	TM5	peptides,	but	not	TM7	peptides,	dramatically	decreased	the	amount	of	positive	PLA	products	in	HEK293	cells	co-expressing	OX1R
and	CCK1R	(Fig.	5B,	d	and	e,	C),	confirming	the	BRET	results	showing	that	TM5	peptides	disrupted	the	heterodimerization	of	OX1R	and	CCK1R.
Fig.	4	FRET	assays	of	heterodimerization	of	OX1R	and	CCK1R.
(A)	FRET	imaging	of	constitutive	OX1R–CCK1R	heteromeric	interactions	in	living	cells.	HEK293	cells	were	transiently	transfected	with	the	plasmids	encoding	(a)	OX1R-eYFP,	(b)	CCK1R-eCFP,	(c)	α1b-adrenoceptor-eCFP	and	OX1R-eYFP,	or	(d)	CCK1R-
eCFP	and	OX1R-eYFP.	Left-hand	panels,	CFP;	center	panels,	YFP;	right-hand	panels,	corrected	FRET.
(B)	Normalized	FRET	values,	calculated	as	described	in	Experimental	Procedures.	Data	represent	means	±	SEM	of	four	independent	experiments.	Statistical	analysis	was	performed	by	one-way	ANOVA	followed	by	Tukey’'s	multiple	comparison	post	hoc
test.	**,	p	<	0.01	vs.	other	groups.
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3.5.3.5	G-protein	activation	patterns	associated	with	OX1R	and	CCK1R	heterodimers
BRET2	assays	were	performed	to	determine	the	activation	patterns	of	Gαi2,	Gαq,	Gα12,	Gα13,	and	Gαs	in	association	with	heterodimers.	The	BRET2	probe	measured	the	distance	between	the	helical	domain	of	Gα	(Gα-Rluc8)
and	the	N-terminus	of	Gγ2	(GFP2-Gγ2)	during	GDP–GTP	exchange.	The	BRET2	signal	was	reduced	following	receptor	activation	[20,21].
We	next	measured	BRET2	signals	in	HEK293	cells	co-transfected	with	plasmids	expressing	GFP2-tagged	Gγ2	and	Gβ1-	and	Rluc8-tagged	Gα	[Gαq-Rluc8	(A);	Gαi2-Rluc8	(B);	Gα12-Rluc8	(C);	Gα13-Rluc8	(D);	and	Gαs-Rluc8	(E)],
as	well	as	pcDNA3.1-OX1R	and/or	pcDNA3.1-CCK1R	(Fig.	6).	The	cells	were	stimulated	with	100	nM	orexin-A	and/or	1000	nM	CCK	(26–33).
Fig.	5	Confirmation	of	OX1R	and	CCK1R	heterodimers	by	in	situ	proximity	ligation	assay	(PLA).
(A)	In	situ	PLA	was	performed	in	HT-29	cells	to	detect	heterodimers	between	endogenously	expressed	OX1R	and	CCK1R.	HT-29	cells	were	incubated	with	(a)	anti-OX1R	antibody	(control)	or	(b)	anti-CCK1R	antibody	and	anti-OX1R	antibody.	Punctate
fluorescent	signals	(red	dots)	indicating	close	proximity	of	OX1R	and	CCK1R,	implying	heterodimer	formation,	were	revealed	by	confocal	microscopy.
(B)	Detection	of	OX1R	and	CCK1R	heterodimers	in	HEK293	cells.	Confocal	microscopy	images	from	PLA	experiments	performed	in	HEK293	cells	expressing	(a)	OX1R	alone,	(b)	α1b-adrenoceptor	and	OX1R,	or	(c)	both	OX1R	and	CCK1R.	HEK293	cells
expressing	OX1R	and	CCK1R	were	treated	with	HIV	TAT–fused	TM	peptides	(10	μM)	corresponding	to	(d)	TM5	or	(e)	TM7	of	OX1R.	Heteromeric	complexes	appear	as	red	spots	and	cell	nuclei	in	blue	(DAPI).	Scale	bars,	25	μm.
(C)	In	situ	PLA	signals,	signifying	the	OX1R–CCK1R	interaction,	were	quantified	as	blobs/cell.	Data	represent	means	±	SEM	of	three	independent	experiments.	Statistical	significance	was	assessed	by	a	paired	Student’'s	t-test.	**,	p	<	0.01	vs.	OX1R
alone	or	α1b-adrenoceptor	and	OX1R	group;	##,	p	<	0.01	for	the	indicated	pairs;	ns,	not	significant.
alt-text:	Fig.	5
We	observed	substantial	reductions	in	BRET2	signals	for	Gαq,	Gα12,	Gα13-Rluc,	and	GFP2-Gγ2	when	HEK293	cells	expressing	OX1R	alone	were	stimulated	with	orexin-A,	and	for	Gαq,	Gαi2,	Gα12,	Gα13-Rluc,	and	GFP2-Gγ2
when	HEK293	cells	expressing	CCK1R	alone	were	stimulated	with	CCK	(26–33)	(Fig.	6A,	B,	C,	and	D).	Taken	together,	these	findings	indicate	that	OX1R	couples	to	Gαq,	Gα12,	and	Gα13,	whereas	CCK1R	couples	to	Gαq,	Gαi2,	Gα12,
and	Gα13.	Interestingly,	when	compared	with	HEK293	cells	expressing	OX1R	alone,	BRET2	signals	for	Gαi2,	Gα12-Rluc8,	and	GFP2-Gγ2	subunits	were	further	reduced	when	HEK293	cells	co-expressing	both	OX1R	and	CCK1R	were
stimulated	with	orexin-A,	indicating	that	OX1R	and	CKK1R	heterodimers	induce	unique	patterns	of	G-protein	activation	upon	stimulation	with	a	single	agonist	(Fig.	6B	and	C).
Furthermore,	in	comparison	with	cells	treated	with	a	single	agonist,	HEK293	cells	co-expressing	OX1R	and	CCK1R	exhibited	significantly	lower	BRET2	signals	for	Gαq,	Gαi2,	Gα12,	Gα13-Rluc8,	and	GFP2-Gγ2	 following	 co-
stimulation	with	orexin-A	and	CCK	 (26–33)	(Fig.	6A,	B,	C,	 and	D).	 These	 findings	 suggest	 that	 dual-agonist	 occupancy	 of	OX1R	 and	CCK1R	heterodimers	 induces	 unique	 conformational	 changes	 in	 these	 receptors,	 reducing	 the
dissociation	of	G-protein	subunits.	Notably,	however,	BRET2	signals	for	Gαs-Rluc8	and	GFP2-Gγ2	were	unaltered,	suggesting	that	heterodimerization	between	OX1R	and	CCK1R	has	little	effect	on	Gαs	activation	after	stimulation	with
orexin-A	and/or	CCK	(26–33)	(Fig.	6E).
To	clarify	the	effect	of	OX1R	and	CCK1R	heterodimerization	on	G-protein	activation,	we	incubated	HEK293	cells	co-expressing	OX1R	and	CCK1R	with	HIV	TAT–fused	TM	peptides	corresponding	to	TM5	or	TM7	of	OX1R,	and
Fig.	6	BRET	analysis	of	the	effects	of	OX1R–CCK1R	heterodimerization	on	Gα	protein	subunit	activation.
HEK293	cells	expressing	OX1R	and/or	CCK1R	were	stimulated	with	100	nM	orexin-A	and/or	1000	nM	CCK	(26–33)	for	1	min,	and	the	levels	of	expression	of	GFP2-Gγ2,	Gβ1,	and	(A)	Gαq-Rluc8,	(B)	Gαi2-Rluc8,	(C)	Gα12-Rluc8,	(D)	Gα13-Rluc8,	or	(E)	Gαs-
Rluc8	were	measured.	Data	represent	means	±	SEM	of	at	least	four	independent	experiments.	##,	p	<	0.01,	cells	co-expressing	both	OX1R	and	CCK1R	treated	with	100	nM	orexin-A	vs.	cells	expressing	OX1R	alone;	**,	p	<	0.01,	cells	co-expressing	both	OX1R
and	CCK1R	treated	with	100	nM	orexin-A	and	1000	nM	CCK	(26–33)	vs.	orexin-A	or	CCK	(26–33)	alone;	ns:	not	significant,	as	determined	by	a	paired	Student’'s	t-test.
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then	observed	the	activation	patterns	of	Gαq	or	Gαi2	 in	association	with	heterodimers.	BRET2	 signals	 for	Gαq	and	GFP2-Gγ2	 subunits	were	significantly	 reduced	after	 incubation	with	HIV	TAT–fused	TM5,	but	not	TM7,	 following
treatment	of	orexin-A	or/and	CCK	(26–33)	(Fig.	7A).	Orexin-A–induced	Gαi2	activation	was	unexpected	after	incubation	with	HIV	TAT–fused	TM5,	because	OX1R	is	thought	to	couple	to	Gαq,	Gα12,	and	Gα13,	and	orexin-A	is	unable	to
bind	CCK1R	(Fig.	7B).	This	observation	suggests	 that	 the	orexin-A–induced	Gαi2	activation	 is	 triggered	by	heterodimerization	of	OX1R	and	CCK1R.	CCK	 (26–33)	did	not	modify	 the	Gαi2	 activation	profile	 in	 the	presence	 of	HIV
TAT–fused	TM5	or	TM7	peptide,	indicating	that	OX1R–CCK1R	heterodimers	or	CCK1R	alone	can	couple	to	Gαi2	protein	(Fig.	7B).	Our	earlier	results	showed	that	OX1R–CCK1R	heterodimers	decreased	Gαi2	activation	by	co-stimulation
with	orexin-A	and	CCK	(26–33)	(Fig.	6B).	By	contrast,	Gαi2	activation	was	elevated	after	incubation	with	HIV	TAT–fused	TM5,	but	not	TM7	(Fig.	7B).	These	observations	are	consistent	with	the	conformational	changes	in	OX1R–CCK1R
heterodimers	induced	by	TM5	peptides.
3.6.3.6	OX1R	and	CCK1R	heterodimerization	does	not	alter	recruitment	of	β-arrestins
Stimulation	of	HEK293	cells	expressing	OX1R-Rluc	and	β-arrestin1-eGFP	with	100	nM	orexin-A	resulted	in	a	robust	and	continually	increasing	ligand-induced	BRET	signal,	indicating	the	recruitment	of	β-arrestin1	to	activated
OX1R	(Fig.	8A).	Incubation	of	these	cells	with	1000	nM	CCK	(26–33)	alone	did	not	increase	BRET	signals,	whereas	co-treatment	of	these	cells	with	orexin-A	and	CCK	(26–33)	resulted	in	a	kinetic	profile	similar	to	that	observed	upon
treatment	with	orexin-A	alone	(Fig.	8A).	Orexin-A	treatment	of	cells	transfected	with	untagged	CCK1R,	OX1R-Rluc,	and	β-arrestin1-EGFP	increased	BRET	signals,	with	a	similar	kinetic	profile	but	reduced	magnitude	(Fig.	8B).	However,
incubation	 of	 cells	 co-expressing	CCK1R	and	OX1R	with	CCK	 (26–33)	 increased	BRET	 signals,	 indicating	 the	proximity	 of	CCK1R	and	OX1R	 in	 heteromeric	 complexes	 that	 recruit	 β-arrestin1	 (Fig.	 8B).	 Similarly,	 β-arrestin2	was
recruited	to	these	heteromeric	complexes	in	a	ligand-dependent	manner	(Fig.	8C	and	D).
Fig.	7	Effects	of	HIV	TAT–TM	peptides	on	Gα	protein	subunit	activation.
HEK293	cells	co-expressing	OX1R	and	CCK1R	were	incubated	at	37	°C	for	2	h	with	HIV	TAT–fused	TM	peptides	(10	μM)	corresponding	to	TM5	or	TM7	of	OX1R.	BRET	was	used	to	analyze	the	levels	of	expression	of	GFP2-Gγ2,	Gβ1,	and	(A)	Gαq-Rluc8	or
(B)	Gαi2-Rluc8,	stimulated	with	100	nM	orexin-A	and/or	1000	nM	CCK	(26–33)	for	1	min.	Data	represent	means	±	SEM	of	four	independent	experiments.	Statistical	significance	was	assessed	by	Student’'s	t-test,	comparing	cells	treated	with	TM5	or	TM7	with
untreated	cells	(**,	p	<	0.01;	ns:	not	significant,	p	>	0.05).
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When	the	experiment	was	repeated	following	exchange	of	energy	donor,	stimulation	of	HEK293	cells	expressing	CCK1R-Rluc,	β-arrestin1-eGFP,	and	untagged	OX1R	with	100	nM	orexin-A	resulted	in	a	robust	and	continually
increasing	ligand-induced	BRET	signal,	indicating	the	recruitment	of	β-arrestin1	and	β-arrestin2	to	CCK1R	by	orexin-A,	dependent	on	OX1R	expression	(Fig.	S2).
3.7.3.7	Heterodimerization	of	OX1R	and	CCK1R	decreases	NFAT-RE	and	SRF-RE	activity
OX1R	and	CCK1R	couple	to	Gαq	or	Gα12	and	induce	transcriptional	activation	via	NFAT-RE	and	SRF-RE.	To	determine	the	effects	of	OX1R	and	CCK1R	heterodimers	on	downstream	signaling,	we	measured	the	activities	of
NFAT-RE	and	SRF-RE	in	HEK293-OX1R,	HEK293-CCK1R,	and	HEK293-OX1R/CCK1R	cells.	Treatment	of	HEK293	cells	co-expressing	OX1R	and	CCK1R	with	orexin-A	or	CCK	(26–33)	resulted	in	significantly	lower	NFAT-RE	activity	than
similar	treatment	of	cells	expressing	OX1R	or	CCK1R	alone	(Fig.	9A).	In	addition,	dual-agonist	treatment	of	HEK293	cells	co-expressing	both	receptors	further	decreased	NFAT-RE	activity	(Fig.	9A).	Similarly,	although	CCK	(26–33)
treatment	increased	SRF-RE	activity	in	HEK293-CCK1R	cells,	SRF-RE	activity	was	significantly	lower	in	HEK293-OX1R/CCK1R	cells	stimulated	with	CCK	(26–33),	and	dual-agonist	treatment	further	decreased	SRF-RE	activity	(Fig.	9C).
These	findings	indicate	that	dual-agonist	occupancy	of	OX1R	and	CCK1R	heterodimers	decreases	Gαq-	and	Gα12-dependent	downstream	signaling.
Fig.	8	Characterization	of	β-arrestin	recruitment	to	OX1R–CCK1R	heterodimers.
HEK293	cells	transiently	co-expressing	OX1R-Rluc	and	(A,	B)	β-arrestin1-eGFP	or	(C,	D)	β-arrestin2-eGFP	in	the	absence	(A,	C)	or	presence	(B,	D)	of	CCK1R	were	monitored	by	extended	BRET	for	10	min	at	37	°C	to	generate	kinetic	curves.	Following
the	addition	of	orexin-A	(100	nM)	and/or	CCK	(26–33)	(1000	nM)	or	vehicle,	monitoring	was	continued	for	an	additional	50	min.	Data	represent	means	±	SEM	of	four	independent	experiments.
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To	further	clarify	the	effect	of	OX1R	and	CCK1R	heterodimers	on	NFAT-RE	and	SRF-RE,	we	incubated	HEK293	cells	co-expressing	with	OX1R	and	CCK1R	with	HIV	TAT–fused	TM	peptides	corresponding	to	TM5	or	TM7	of
OX1R.	Incubation	with	HIV	TAT–fused	TM5,	but	not	TM7,	resulted	in	significantly	higher	NFAT-RE	activity	than	treatment	with	orexin-A	or	CCK	(26–33)	alone	(Fig.	9B).	Finally,	 incubation	with	TM5	decreased	 induction	of	SRF-RE
activity	 by	 orexin-A	 treatment,	 but	 increased	 SRF-RE	 activity	 in	 response	 to	 CCK	 (26–33)	 treatment	 (Fig.	 9D).	 This	 observation	 is	 consistent	 with	 our	 earlier	 data	 that	 TM5	 impaired	 the	 conformation	 of	 OX1R	 and	 CCK1R
heterodimerization.
3.8.3.8	Heterodimerization	of	OX1R	and	CCK1R	alters	the	cell	migration	using	RTCA
The	xCELLigence	system	records	the	electrical	impedance	of	a	gold-sensing	electrode	beneath	a	cultured	cell	layer	in	the	form	of	arbitrary	CI	units,	and	can	thus	monitor	cell	migration	in	real	time.	The	CI	values	of	HT-29	cells
treated	with	both	orexin-A	(100	nM)	and	CCK	(26–33)	(1000	nM)	were	significantly	 lower	than	those	of	cells	treated	with	orexin-A	or	CCK	(26–33)	alone,	suggesting	that	dual-agonist	occupancy	of	OX1R	and	CCK1R	heterodimers
affects	the	migration	of	HT-29	human	colon	cancer	cells	(Fig.	10).	The	cell	migration	data	provide	further	evidence	in	support	of	the	hypothesis	that	heterodimerization	of	OX1R	and	CCK1R	mediates	a	unique	response	of	HT-29	cells	to
dual-agonist	stimulation.
Fig.	9	Effect	of	OX1R	and	CCK1R	heterodimerization	on	NFAT-RE	and	SRF-RE	activities.
(A	and	C)	Twenty-four	hours	after	transfection	with	NFAT-RE	(A)	or	SRF-RE	(C),	with	RL-Tk,	HEK293-OX1R,	HEK293-CCK1R,	and	HEK293-OX1R/CCK1R	cells	were	treated	with	100	nM	orexin-A	and/or	1000	nM	CCK	(26–33)	for	6	h	prior	to	harvest.
(B	and	D)	Twenty-four	hours	after	transfection	with	NFAT-RE	(B)	or	SRF-RE	(D),	with	RL-Tk,	HEK293	cells	co-expressing	OX1R	and	CCK1R	were	incubated	at	37	°C	for	2	h	with	HIV	TAT–fused	TM	peptides	(10	μM)	corresponding	to	TM5	or	TM7	of
OX1R.	Cells	were	treated	with	100	nM	orexin-A	or	1000	nM	CCK	(26–33)	for	6	h	prior	to	harvesting.	Firefly	and	Renilla	luciferase	activities	were	assayed	using	a	Dual-Luciferase	Reporter	Assay	System,	and	ratios	of	firefly	to	Renilla	luciferase	luminescence
were	calculated.	Data	represent	means	±	SEM	of	at	least	four	independent	experiments.	Statistical	analysis	was	performed	by	one-way	ANOVA	followed	by	Tukey’'s	multiple	comparison	post	hoc	test.	##,	p	<	0.01,	cells	co-expressing	both	OX1R	and	CCK1R
treated	with	orexin-A	or	CCK	(26–33)	vs.	cells	expressing	OX1R	or	CCK1R	alone;	**,	p	<	0.01,	cells	co-expressing	both	OX1R	and	CCK1R	treated	with	orexin-A	and	CCK	(26–33)	vs.	orexin-A	or	CCK	(26–33)	alone;	&&,	p	<	0.01,	TM5	treated	vs.	untreated	cells;
ns:	not	significant,	p	>	0.05.
alt-text:	Fig.	9
4.4	Discussion
It	is	well	established	that	GPCRs	can	exist	as	monomeric	entities	and	form	dimers	and/or	oligomers	when	expressed	in	a	heterologous	cell	system,	as	well	as	in	native	tissues.	For	example,	human	muscarinic
M1	receptor	is	present	on	the	basolateral	surface	of	cells	as	a	75:25	mixture	of	receptor	monomers	and	dimers/oligomers	[22].	However,	the	proportion	of	these	forms	in	a	receptor	population	can	be	regulated	by
interaction	with	ligands	or	other	modulators,	and	these	effects	have	major	implications	for	receptor	function	and	behavior.
Accumulating	evidence	indicates	that	GPCRs	are	involved	in	cancer	development,	including	proliferation,	migration,	and	invasion.	Furthermore,	GPCR	dimerization	is	regarded	as	important	in	fine-tuning	the
behavior	of	cancer	cells.	For	example,	a	synthetic	peptide	that	blocks	the	dimerization	of	CXCR4	inhibits	malignant	cell	migration	in	response	to	CXCL12/SDF-1A	[23,24].
Both	orexin	and	cholecystokinin	receptors	are	involved	in	migration	of	human	colon	cancer	cells.	In	this	study,	we	found	that	OX1R	and	CCK1R	were	co-expressed	in	the	human	colon	cancer	cell	line	HT-29.	In
addition,	we	analyzed	OX1R	and	CCK1R	dimerization	by	BRET,	FRET,	and	in	situ	PLA	assays	in	HEK293	cells.	The	PLA	results	confirmed	that	OX1R	and	CCK1R	heterodimerize	in	HT-29	cells,	indicating	that	these
dimers	are	functional	in	vivo.	Our	investigation	of	the	effects	of	interfering	peptides	on	interactions	between	OX1R	and	CCK1R	heterodimers	revealed	that	peptides	encoding	TM5,	but	not	TM7,	could	bind	to	OX1R,
suggesting	that	TM5	is	involved	in	interface	formation.	These	findings	suggest	that	these	interfering	peptides	have	therapeutic	potential,	as	they	can	disrupt	dimerization	and	influence	receptor	function.	Indeed,	a
peptide	derived	from	TM6	of	β2AR	disrupts	dimer	formation	and	decreases	receptor	function	[25],	whereas	a	synthetic	peptide	that	disrupts	the	dimerization	of	CXCR4	inhibits	malignant	cell	migration	in	response	to
CXCL12/SDF-1A	[24].
GPCR	dimerization	is	of	physiological	relevance	and	often	acts	as	the	first	step	in	the	induction	of	intracellular	signals	in	response	to	ligand	binding	[26–28].	GPCR	dimer–monomer	 interconversion	may	be
important	for	precise	control	of	signal	transduction	[29–31].	For	example,	heterodimerization	of	APJ	and	the	κ-opioid	receptor	(KOR)	affects	cAMP	accumulation	after	treatment	with	apelin-13	or	DynA(1–13)	[32].	In
the	ventral	tegmental	area,	heterodimers	of	orexin	receptor	and	corticotropin-releasing	factor	receptor	serve	as	targets	for	cocaine	and	promote	long-term	disruption	of	negative	crosstalk	between	orexin-A	and	CRF
[33].	Heteromultimerization	of	cannabinoid	(CB)	1	receptor	and	OX1R	generates	a	unique	complex,	in	which	both	protomers	are	regulated	by	orexin-A	[34].	We	also	found	that	heterodimerization	of	OX1R	and	CCK1R
led	to	alterations	in	signaling.	Although	OX1R	and	CCK1R	were	previously	reported	to	couple	with	Gαq	and	Gα12/13,	respectively,	BRET	revealed	that	co-stimulation	of	both	OX1R	and	CCK1R	in	HT-29	cells	decreased
the	dissociation	of	Gαq,	Gαi,	Gα12,	and	Gα13	subunits	following	stimulation	with	both	orexin-A	and	CCK	(26–33),	indicating	that	activation	of	Gαq,	Gαi,	Gα12,	and	Gα13	may	be	reduced	by	dual-agonist	occupancy	of
OX1R/CCK1R	heterodimers.	By	 contrast,	 activation	 of	Gαs	was	 not	 significantly	 changed.	 Indeed,	 occupancy	 by	 the	 dual	 agonists	 norepinephrine	 (NE)	 and	 angiotensin	 II	 (AngII)	 causes	 the	 conformation	 of	 the
heterodimer	of	AngII	AT1	receptor	(AT1-R)	and	NE	α2C-adrenergic	receptor	(α2C-AR)	to	differ	from	that	induced	by	individual	active	protomers,	and	triggers	atypical	Gαs-cAMP–PKA	signaling	[35].	Thus,	dual-agonist
occupancy	may	result	in	novel	functional	activities	of	GPCR	heterodimers,	suggesting	a	promising	new	target	for	therapeutics.	The	findings	reported	in	the	present	study	are	consistent	with	this,	in	that	dual-agonist
stimulation	of	OX1R	and	CCK1R	induced	significant	changes	in	downstream	signaling,	suggesting	that	GPCR	dimerization	is	an	underlying	mechanism	of	fine-tuning	of	receptor	function,	especially	upon	dual-agonist
stimulation.
Fig.	10	Heterodimerization	of	OX1R	and	CCK1R	alters	cancer	cell	migration.
Migration	CI	curves	of	HT-29	cells	during	differentiation,	measured	by	RTCA	assay.	HT-29	cells	were	treated	with	orexin-A	(100	nM)	and/or	CCK	(26–33)	(1000	nM),	and	the	resultant	CI	growth	curves	were	compared.	Data	represent	means	±	SEM	of
four	independent	experiments.
alt-text:	Fig.	10
We	used	reporter	gene	assays	to	measure	the	activation	of	Gα	subunits	after	dual-agonist	stimulation.	Upon	activation	of	GPCRs,	the	Gα	protein	subunit	dissociates	from	the	βγ-dimeric	subunit,	 initiating	a
cascade	of	downstream	second-messenger	pathways.	This	may	eventually	induce	gene	transcription	by	various	REs,	including	cAMP	response	element	(CRE),	NFAT-RE,	serum	response	element	(SRE),	and	SRF-RE,
corresponding	to	the	Gαs,	Gαi,	Gαq,	and	Gα12	pathways,	respectively.	The	results	of	this	study	also	suggest	that	dual-agonist	stimulation	reduces	NFAT-RE	and	SRF-RE	activities,	suggesting	that	decreased	Gαq	and
Gα12	activation	also	affects	downstream	gene	transcription.
Furthermore,	OX1R	and	CCK1R	heterodimerization	does	not	alter	the	recruitment	of	β-arrestins,	which	mediate	the	internalization	of	heterodimers,	resulting	in	reduced	G-protein	activation	and	downstream
gene	 transcription.	 Several	 studies	 suggest	 coordinated	 trafficking	 of	 GPCR	 heterodimers	 [34,36,37],	 but	 these	 reports	 are	 contradicted	 by	 others	 suggesting	 that	 monomeric	 receptors	 predominate	 following
internalization	[38].	Our	findings	did	not	resolve	whether	native	OX1R	and	CCK1R	monomeric	or	OX1R	and	CCK1R	heterodimerization	enter	the	clathrin-mediated	endocytosis	pathway,	but	it	is	possible	that	stabilized
receptors	undergo	internalization.	However,	our	results	show	that	Gαq	activation	was	reduced	when	OX1R–CCK1R	heterodimerization	was	stimulated	with	orexin-A	or/and	CCK	(26–33).	Meanwhile,	Gαi2	and	Gα12
were	activated	by	treatment	with	orexin-A	or	CCK	(26–33)	alone,	but	not	by	co-stimulation.	Taken	together,	these	findings	indicate	that	orexin-A	may	acquire	the	capacity	to	activate	Gαi2	and	Gα12	when	OX1R	and
CCK1R	heterodimerize.
To	further	investigate	whether	OX1R–CCK1R	heterodimers	affect	cell	migration,	we	performed	xCELLigence	assays.	Cells	co-stimulated	with	orexin-A	and	CCK	(26–33)	migrated	significantly	less	than	cells
treated	with	 orexin-A	or	CCK	 (26–33)	 alone.	Thus,	OX1R–CCK1R	dimerization	may	decrease	 the	migration	 of	 human	 colon	 cancer	 cells.	However,	 combining	 the	 evidence	 from	 the	 effects	 of	 co-stimulation	with
agonists	of	these	two	receptors	on	cancer	cell	migration,	the	results	indicate	that	the	dimerization	may	play	important	roles	for	these	two	receptors	exerting	their	functional	activities.
Recent	studies	show	that	monovalent	drugs	specific	for	GPCR	heterodimers	and	bivalent	ligands	are	powerful	tools	for	evaluating	the	activation	of	signaling	pathways	and	cellular	responses	induced	by	GPCR
dimerization	and	oligomerization.	Because	heterodimerization	of	OX1R	and	CCK1R	significantly	decreases	the	migration	of	human	colon	cancer	cells,	future	studies	should	investigate	the	effects	of	monovalent	drugs
or	bivalent	ligands	specific	for	OX1R–CCK1R	heterodimers	on	the	growth	and	metastasis	of	solid	tumors,	including	colon	cancer.
In	conclusion,	this	study	is	the	first	to	report	that	OX1R	forms	heterodimers	with	CCK1R,	and	that	G-protein–dependent	signal	transduction	is	reduced	by	orexin-A	and	CCK	(26–33)	co-stimulation.	Dimerization
of	OX1R	 and	CCK1R	may	 inhibit	 the	Gαq/Gαi/Gα12/Gα13	 signaling	 pathways,	 as	 well	 as	 downstream	NFAT-RE	 and	 SRF-RE	 activation,	 but	 activate	 the	 β-arrestin	 signaling	 pathway.	 Furthermore,	 OX1R–CCK1R
heterodimers	may	mediate	the	migration	of	HT-29	cells	in	an	agonist-dependent	manner,	indicating	that	the	balance	between	orexin	and	CCK	in	vivo	may	fine-tune	the	in	vivo	metastasis	of	colon	tumors.	However,	in
vivo	investigations	are	required	to	further	evaluate	the	importance	of	OX1R–CCK1R	dimerization	in	cancer.
Supplementary	data	to	this	article	can	be	found	online	at	http://dx.doi.org/10.1016/j.bbamcr.2017.03.003.
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Additional	BRET	assays	were	performed	to	determine	whether	ligands	induce	heterodimerization.	BRET	ratios	were	observed	in	HEK293	cells	co-transfected	with	OX1R-Rluc	and	CCK1R-eGFP
at	 a	 1:3	 ratio	 and	 treated	with	 orexin-A,	 in	 cells	 treated	with	 CCK	 (26–33)	 alone,	 and	 in	 cells	 treated	 for	 10	min	with	 orexin-A	 and	 CCK	 (26–33)	 (Fig.	2C).	 The	 BRET	 ratios	 of	 these	 cells	 were
0.364	±	0.010,	0.361	±	0.009,	and	0.366	±	0.012,	respectively.	When	the	experiment	was	repeated	following	energy	donor–acceptor	exchange	between	the	two	receptors,	orexin-A	or/and	CCK	(26–33)-
induced	BRET	ratios	remained	unchanged	(Fig.	2D).	These	results	 implied	that	 ligand	binding	might	not	be	necessary	 for	heterodimerization	of	OX1R	and	CCK1R.	Moreover,	sequential	addition	of
orexin-A	and	CCK	(26–33)	did	not	similarly	alter	the	BRET	ratio	between	OX1R	and	CCK1R	(Fig.	S1).
When	 the	 experiment	was	 repeated	 following	 exchange	 of	 energy	 donor,	 stimulation	 of	HEK293	 cells	 expressing	CCK1R-Rluc,	 β-arrestin1-eGFP,	 and	 untagged	OX1R	with	 100	nM	 orexin-A
resulted	in	a	robust	and	continually	increasing	ligand-induced	BRET	signal,	indicating	the	recruitment	of	β-arrestin1	and	β-arrestin2	to	CCK1R	by	orexin-A,	dependent	on	OX1R	expression	(Fig.	S2).
The	following	are	the	supplementary	data	related	to	this	article.
Fig.	S1	Orexin-A	and	CCK	(26-33)	sequential	stimulation	effects	on	the	OX1R	and	CCK1R	heterodimer.
BRET	was	measured	in	HEK293	cells	co-expressing	OX1R-Rluc	and	CCK1R-eGFP	and	stimulated	or	not	for	10	min	with	orexin-A	(100	nM),	CCK	(26-33)	(1000	nM)	or	both	orexin-A	+	CCK	(26-33),	as	indicated.	For	orexin-A	+	CCK	(26-33)	co-
stimulation,	experiments	were	performed	by	preincubating	with	orexin-A	(5	min)	before	CCK	(26‐–33)	injection	(A)	or	preincubating	with	CCK	(26‐–33)	before	orexin-A	injection	(B).	BRET	ratios	were	analyzed	and	expressed	as	the	mean	±	SEM	of	four
experiments	(one-way	analysis	of	variance;	ns,	not	significant,	p	>	0.05).
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Fig.	S2	Heterodimerization	of	OX1R	and	CCK1R	does	not	alter	their	interaction	with	β-arrestins.
HEK293	cells	transiently	co-expressing	CCK1R-Rluc	and	(A,	B)	β-arrestin1-eGFP	or	(C,	D)	β-arrestin2-eGFP	in	the	absence	(A,	C)	or	presence	(B,	D)	of	OX1R	were	monitored	by	extended	BRET	for	10	min	at	37	°C	to	generate	kinetic	curves.	Following
the	addition	of	orexin-A	(100	nM)	and/or	CCK	(26‐–33)	(1000	nM)	or	vehicle,	monitoring	was	continued	for	an	additional	50	min.	Data	represent	the	mean	±	SEM	of	four	independent	experiments.
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